Annual public health and economic benefits of seasonal influenza vaccination: a European estimate

被引:106
作者
Preaud, Emmanuelle [1 ]
Durand, Laure [2 ]
Macabeo, Berengere [2 ]
Farkas, Norbert [3 ]
Sloesen, Brigitte [4 ]
Palache, Abraham [5 ]
Shupo, Francis [6 ]
Samson, Sandrine I. [1 ]
机构
[1] Sanofi Pasteur MSD, F-69367 Lyon, France
[2] Sanofi Pasteur, F-69007 Lyon, France
[3] Novartis Vaccines & Diagnost AG, CH-4056 Basel, Switzerland
[4] GlaxoSmithKline, Rixensart, Belgium
[5] Abbott, NL-1381 CP Weesp, Netherlands
[6] Creativ Ceut Ltd, London SE1 9QQ, England
关键词
Influenza; Public health policy; Vaccines and immunization; Modeling; Epidemiology; COST-EFFECTIVENESS; EXCESS MORTALITY; ENGLAND; BURDEN; NORWAY; IMPACT; UNION;
D O I
10.1186/1471-2458-14-813
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Vaccination is currently the most effective means of preventing influenza infection. Yet evidence of vaccine performance, and the impact and value of seasonal influenza vaccination across risk groups and between seasons, continue to generate much discussion. Moreover, vaccination coverage is below recommended levels. Methods: A model was generated to assess the annual public health benefits and economic importance of influenza vaccination in 5 WHO recommended vaccination target groups (children 6 - 23 months of age; persons with underlying chronic health conditions; pregnant women; health care workers; and, the elderly, 65 years of age) in 27 countries of the European Union. Model estimations were based on standard calculation methods, conservative assumptions, age-based and country-specific data. Results: Out of approximately 180 million Europeans for whom influenza vaccination is recommended, only about 80 million persons are vaccinated. Seasonal influenza vaccination currently prevents an annual average of between 1.6 million and 2.1 million cases of influenza, 45,300 to 65,600 hospitalizations, and 25,200 to 37,200 deaths. To reach the 75% vaccination coverage target set by the EU Council Recommendation in 2009, an additional 57.4 million person would need to be vaccinated in the elderly and other risk groups. By achieving the 75% target rate set in EU-27 countries, average annual influenza-related events averted would increase from current levels to an additional +1.6 to +1.7 million cases, +23,800 to +31,400 hospitalization, +9,800 to +14,300 deaths, +678,500 to +767,800 physician visits, and +883,800 to +1,015,100 lost days of work yearly. Influenza-related costs averted because of vaccination would increase by an additional +(sic)190 to +(sic)226 million yearly, in vaccination target groups. Conclusions: Full implementation of current influenza vaccination recommendations of 75% vaccination coverage rate (VCR) in Europe by the 2014-2015 influenza season could immediately reduce an important public health and economic burden.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Estimating the full health and economic benefits of current and future influenza vaccines
    Lafond, K. E.
    Gharpure, R.
    Dugan, V. G.
    Azziz-Baumgartner, E.
    BMC MEDICINE, 2023, 21 (01)
  • [32] The Dangers of Influenza and Benefits of Vaccination in Adults With Chronic Health Conditions
    Schaffner, William
    McElhaney, Janet
    Rizzo, Albert A.
    Savoy, Margot
    Taylor, Allen J.
    Young, Melissa
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2018, 26 (06) : 313 - 322
  • [33] Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany
    Damm, Oliver
    Eichner, Martin
    Rose, Markus Andreas
    Knuf, Markus
    Wutzler, Peter
    Liese, Johannes Guenter
    Krueger, Hagen
    Greiner, Wolfgang
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2015, 16 (05) : 471 - 488
  • [34] Public Health and Economic Impact of 7-valent Pneumococcal Conjugate Vaccination in an Influenza Pandemic in the US
    Rubin, J. L.
    McGarry, L. J.
    Klugman, K.
    Strutton, D.
    Ciuryla, V.
    Gilmore, K.
    VACCINE, 2008,
  • [35] Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico
    Ruiz-Palacios, Guillermo M.
    Beigel, John H.
    Guerrero, Maria Lourdes
    Bellier, Lucile
    Tamayo, Ramiro
    Cervantes, Patricia
    Alvarez, Fabian P.
    Galindo-Fraga, Arturo
    Aguilar-Ituarte, Felipe
    Guillermo Lopez, Juan
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (04) : 827 - 835
  • [36] Seasonal influenza vaccination and absenteeism in health-care workers in two subsequent influenza seasons (2016/17 and 2017/18) in an Italian pediatric hospital
    Zaffina, Salvatore
    Gilardi, Francesco
    Rizzo, Caterina
    Sannino, Serena
    Brugaletta, Rita
    Santoro, Annapaola
    Gattinara, Guido Castelli
    degli Atti, Marta Luisa Ciofi
    Raponi, Massimiliano
    Vinci, Maria Rosaria
    EXPERT REVIEW OF VACCINES, 2019, 18 (04) : 411 - 418
  • [37] Cost-Effectiveness of Extending the National Influenza Vaccination Program in South Korea: Does Vaccination of Older Adults Provide Health Benefits to the Entire Population?
    Shin, Gyeongseon
    Kang, Daewon
    Cheong, Hee Jin
    Choi, Sang-Eun
    VACCINES, 2022, 10 (06)
  • [38] Annual economic impacts of seasonal influenza on US counties: Spatial heterogeneity and patterns
    Liang Mao
    Yang Yang
    Youliang Qiu
    Yan Yang
    International Journal of Health Geographics, 11
  • [39] Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic transmission modelling
    Jeanette Dawa
    Gideon O. Emukule
    Edwine Barasa
    Marc Alain Widdowson
    Omu Anzala
    Edwin van Leeuwen
    Marc Baguelin
    Sandra S. Chaves
    Rosalind M. Eggo
    BMC Medicine, 18
  • [40] Impact of European vaccination policies on seasonal influenza vaccination coverage rates: An update seven years later
    Blank, Patricia R.
    van Essen, Gerrit Adrianus
    de Lejarazu, Raul Ortiz
    Kyncl, Jan
    Nitsch-Osuch, Aneta
    Kuchar, Ernest Piotr
    Falup-Pecurariu, Oana
    Maltezou, Helena C.
    Zavadska, Dace
    Kristufkova, Zuzana
    Kassianos, George
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (11) : 2706 - 2714